文献速递眼底病与葡萄膜炎

DRCR视网膜网络对中心型糖尿病黄斑水肿且视力良好眼初始观察管理方案的评估:随机临床试验二次分析

Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2020-01-01

该研究为DRCR视网膜网络Protocol V随机临床试验的事后二次分析,纳入236例中心型糖尿病黄斑水肿且视力≥79个字母(Snellen等效20/25或更好)的患眼,评估初始观察联合视力恶化时才使用阿柏西普的方案。2年随访中34%患眼接受阿柏西普治疗,中位视力字母评分为86.0,多数患眼维持良好视力;基线中央亚区厚度≥300 μm、糖尿病视网膜病变严重程度较高及非研究眼接受DME治疗者更可能需要阿柏西普。

要点

  • 初始观察方案下,2年内仅34%患眼因视力下降接受阿柏西普治疗。
  • 2年时中位视力字母评分86.0(Snellen等效20/20),多数患眼维持良好视力。
  • 基线中央亚区厚度≥300 μm者接受阿柏西普风险比为1.98。

核心结论

  • 多数中心型糖尿病黄斑水肿且视力良好的患眼采用初始观察联合视力恶化时才使用阿柏西普的方案,在2年时维持良好视力且未因视力下降需要阿柏西普。
  • 基线中央亚区厚度较大、糖尿病视网膜病变严重程度较高或非研究眼接受DME治疗的患眼接受阿柏西普的可能性约为其他患眼的2倍。

研究设计与样本

  • 纳入236例1型或2型糖尿病成人患者(236只眼),研究眼为中心型糖尿病黄斑水肿且视力字母评分至少79(Snellen等效20/25或更好),被分配至初始观察组。
  • 干预为初始观察,仅在单次随访视力较基线下降至少10个字母或连续两次随访下降5至9个字母时使用阿柏西普;随访在8周后进行,之后每16周一次,除非视力或OCT中央亚区厚度恶化。

主要发现

  • 236只眼中80只(34%)在2年随访期间接受阿柏西普治疗。
  • 2年时中位视力字母评分为86.0(四分位距89.0-81.0;中位Snellen等效20/20(20/16-20/25))。

关键数值与推荐

  • 初始观察方案中阿柏西普使用标准为:单次随访视力较基线下降至少10个字母,或连续两次随访下降5至9个字母。
  • 随访安排为8周后首次随访,之后每16周一次,除非视力或OCT中央亚区厚度恶化。

临床怎么用

  • 对于中心型糖尿病黄斑水肿且视力良好(20/25或更好)的患眼,可考虑初始观察联合视力恶化时才使用阿柏西普的方案,多数患眼2年内不需要抗VEGF治疗。
  • 基线中央亚区厚度≥300 μm、糖尿病视网膜病变严重程度较高或非研究眼正在接受DME治疗者,接受阿柏西普的可能性较高,应加强监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Among eyes with center-involved diabetic macular edema (CI-DME) and good visual acuity (VA), randomized clinical trial results showed no difference in VA loss between initial observation plus aflibercept only if VA decreased, initial focal/grid laser plus aflibercept only if VA decreased, or prompt aflibercept. Understanding the initial observation approach is relevant to patient management. OBJECTIVE: To assess the DRCR Retina Network protocol-defined approach and outcomes of initial observation with aflibercept only if VA worsened. DESIGN, SETTING, AND PARTICIPANTS: This was a post hoc secondary analyses of a randomized clinical trial of the DRCR Retina Network Protocol V that included 91 US and Canadian sites from November 2013 to September 2018. Participants were adults (n = 236) with type 1 or 2 diabetes, 1 study eye with CI-DME, and VA letter score at least 79 (Snellen equivalent, 20/25 or better) assigned to initial observation. Data were analyzed from March 2019 to November 2019. INTERVENTIONS: Initial observation and follow-up with aflibercept only for VA loss of at least 10 letters from baseline at 1 visit or 5 to 9 letters at 2 consecutive visits. Follow-up occurred at 8 weeks and then every 16 weeks unless VA or optical coherence tomography central subfield thickness worsened. MAIN OUTCOMES AND MEASURES: Whether individuals received aflibercept. RESULTS: Among 236 eyes in 236 individuals (149 [63%] male; median age, 60 years [interquartile range, 53-67 years]) randomly assigned to initial observation, 80 (34%) were treated with aflibercept during 2 years of follow-up. At 2 years, the median VA letter score was 86.0 (interquartile range, 89.0-81.0; median Snellen equivalent, 20/20 [20/16-20/25]). Receipt of aflibercept was more likely in eyes with baseline central subfield thickness at least 300 μm (Zeiss-Stratus equivalent) vs less than 300 μm (45% vs 26%; hazard ratio [HR], 1.98 [95% CI, 1.26-3.13], continuous P = .005), moderately severe nonproliferative diabetic retinopathy (Early Treatment Diabetic Retinopathy Study retinopathy severity level 47) and above vs moderate nonproliferative diabetic retinopathy (retinopathy severity level 43) and below (51% vs 27%; HR, 2.22 [95% CI, 1.42-3.47], ordinal P < .001), and among participants whose nonstudy eye received DME treatment within 4 months of randomization vs not (52% vs 25%; HR, 2.55 [95% CI, 1.64-3.99], P < .001). CONCLUSIONS AND RELEVANCE: Most eyes managed with initial observation plus aflibercept only if VA worsened maintained good vision at 2 years and did not require aflibercept for VA loss. However, the eyes in the trial were approximately twice as likely to receive aflibercept for VA loss if they had greater baseline central subfield thickness, worse diabetic retinopathy severity level, or a nonstudy eye receiving treatment for DME. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01909791.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Glassman AR, Baker CW, Beaulieu WT, et al. Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2020. PMID: 32077907. doi:10.1001/jamaophthalmol.2019.6035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。